Fosamax vs Prolia (Denosumab): Real-World Evidence Comparison

How Each Drug Works

Alendronate and denosumab both reduce bone resorption, but through entirely different pathways. Alendronate is a nitrogen-containing bisphosphonate that binds to hydroxyapatite in bone matrix and inhibits farnesyl pyrophosphate synthase inside osteoclasts, effectively triggering osteoclast apoptosis. Denosumab is a fully human monoclonal antibody that binds RANK Ligand (RANKL), preventing it from activating RANK on osteoclast precursors, which stops osteoclast formation before it starts.

Alendronate: Mechanism and Residual Effect

Bisphosphonates embed into bone mineral and continue acting even after the drug is stopped. This "skeletal depot" effect means alendronate's anti-resorptive action can persist for months to years after discontinuation, which is one reason drug holidays of 1 to 2 years are feasible in lower-risk patients after 5 years of therapy per American Society for Bone and Mineral Research guidance.

Alendronate was approved by the FDA in 1995 and has been available generically since 2008. The 70 mg once-weekly oral tablet is the standard adult dose for osteoporosis treatment.

Denosumab: Mechanism and the Rebound Problem

Denosumab's effect is entirely reversible. RANKL returns to circulation within weeks of a missed injection, osteoclast activity surges, and bone resorption can rebound dramatically. Post-marketing pharmacovigilance data and multiple case series published in the Journal of Bone and Mineral Research document vertebral fracture rates of up to 3 to 7 per 100 patient-years in the 12 to 18 months after denosumab discontinuation without transition to another anti-resorptive agent. This is not a theoretical concern. It is the single most clinically consequential difference between the two drugs.

Landmark Trial Evidence

FIT: Alendronate's Foundational Data

The Fracture Intervention Trial (FIT) remains alendronate's most cited efficacy benchmark. In the vertebral fracture arm (N=2,027 women with existing vertebral fractures), three years of alendronate 5 to 10 mg daily reduced clinical vertebral fractures by 47% compared with placebo (relative risk 0.53, 95% CI 0.41 to 0.68) [1]. Hip fracture risk fell by 51% in the same population. Bone mineral density at the lumbar spine rose by approximately 6.2% from baseline at 36 months.

The FIT non-vertebral fracture trial (N=4,432 women with low BMD but no prevalent vertebral fracture) showed a 36% reduction in clinical fractures over 4 years [1]. These data formed the basis for alendronate's broad prescribing in postmenopausal osteoporosis.

FREEDOM: Denosumab's Key Phase III Data

The FREEDOM trial (N=7,808 postmenopausal women with osteoporosis, T-score between -2.5 and -4.0) tested denosumab 60 mg subcutaneously every 6 months against placebo for 36 months [2]. Denosumab reduced new vertebral fracture risk by 68% (relative risk 0.32, 95% CI 0.26 to 0.41, P<0.001). Non-vertebral fracture risk dropped by 20% and hip fracture risk by 40% compared with placebo [2].

The FREEDOM Extension followed participants for an additional 7 years, reaching 10 years of total exposure in a subset. Lumbar spine BMD continued rising throughout, reaching a mean gain of 21.7% from the original baseline at 10 years, a magnitude not seen in long-term bisphosphonate data.

Head-to-Head Evidence: Which Drug Wins on BMD?

No single published randomized controlled trial has directly compared fracture outcomes between alendronate and denosumab in the same population. The DECIDE trial (N=504) compared the two agents head-to-head for BMD outcomes over 12 months and found denosumab produced significantly greater gains at total hip (3.5% vs 2.6%, P<0.0001) and lumbar spine (5.3% vs 4.2%, P<0.0001) [3]. Femoral neck gains also favored denosumab.

The STAND trial (N=504 postmenopausal women previously on alendronate for at least 6 months) showed that switching to denosumab produced greater BMD increases at all measured sites compared with continuing alendronate at 12 months [4]. Total hip BMD improved by 1.90% with denosumab versus 1.05% with continued alendronate (P<0.0001).

These are surrogate endpoints, not fracture endpoints. The BMD differences, while statistically significant, may not translate into meaningful differences in absolute fracture risk reduction for most patients with moderate-risk osteoporosis.

Real-World Evidence: Registries and Observational Data

The DAPS Observational Cohort

Randomized trial populations are selective. Real-world data from the Danish Osteoporosis Prevention Study and large pharmacy database analyses paint a somewhat different picture. Adherence to weekly oral alendronate in real-world practice is poor. A 2018 systematic review in Osteoporosis International found that only 30 to 40% of bisphosphonate users remain adherent at 12 months, and non-adherence substantially attenuates fracture protection [5].

Denosumab, administered as an injection every 6 months in a clinical setting, shows better persistence rates. A 2020 analysis of U.S. Insurance claims (N=19,832 patients) found 12-month persistence of 71% for denosumab versus 46% for oral bisphosphonates [6]. When adherence is this divergent in practice, denosumab's theoretical BMD advantage is compounded by a real-world adherence advantage.

Renal Impairment Populations

Alendronate is contraindicated when creatinine clearance falls below 35 mL/min (eGFR <35 ml/min) due to risks of renal accumulation. Denosumab carries no such renal restriction. A 2017 analysis in JAMA Internal Medicine of patients with CKD stages 3 to 5 found denosumab was effective and did not worsen renal function over 3 years, though hypocalcemia risk was substantially elevated in CKD stage 4 and 5 patients, requiring vitamin D and calcium co-management [7]. For clinicians managing osteoporosis in chronic kidney disease, this distinction is not academic. It directly determines which drug is safe to prescribe.

Atypical Femoral Fractures and Osteonecrosis of the Jaw

Both drugs carry class risks for atypical femoral fracture (AFF) and osteonecrosis of the jaw (ONJ). Absolute risks are low. The American Society for Bone and Mineral Research Task Force in 2016 estimated AFF incidence at 3.2 to 50 cases per 100,000 person-years for bisphosphonates and a similar but slightly higher range with longer-duration denosumab use [8]. ONJ incidence in osteoporosis (as opposed to oncology doses) is estimated at fewer than 1 in 10,000 to 1 in 100,000 patient-years with either agent.

Dental assessment before starting either drug and regular oral hygiene are standard precautions per Endocrine Society and American Dental Association guidance.

Switching from Fosamax to Prolia: When and How

Switching from alendronate to denosumab is a common clinical scenario, and the evidence supports it under specific conditions. The HealthRX clinical team has developed the following decision framework for evaluating switch candidates.

The HealthRX Alendronate-to-Denosumab Switch Framework

Switch is supported when one or more of the following apply:

1. Persistent GI intolerance to oral bisphosphonate (esophagitis, dysphagia, or intractable reflux) that does not resolve with dosing adjustments.
2. Documented non-adherence to weekly oral dosing despite counseling, confirmed by prescription refill gaps of more than 8 weeks.
3. BMD decline of more than 3 to 5% at any measured site after at least 12 months of verified adherent alendronate therapy.
4. EGFR falling below 35 mL/min, making continued bisphosphonate use contraindicated.
5. Incident fracture on therapy after at least 12 months of adherent bisphosphonate use, suggesting treatment failure.
6. Patient preference for injection-based dosing after shared decision making.

Switch requires caution (discuss with prescribing physician) when:

• The patient has a history of poor adherence to scheduled appointments, because denosumab injections must arrive on time (within a 2-week window of the 6-month interval).
• The patient may need to discontinue therapy in the future without a clear transition plan to a bisphosphonate.
• Baseline 25-hydroxyvitamin D is below 20 ng/mL. Replete vitamin D before starting denosumab to reduce hypocalcemia risk.

The Discontinuation Transition Protocol

Any patient stopping denosumab should transition to an oral bisphosphonate within 4 to 6 months of the last injection. Zoledronic acid (Reclast) 5 mg IV at 6 months after the final denosumab dose is an evidence-supported strategy for attenuating the rebound resorption effect. A 2021 study in the Journal of Bone and Mineral Research (N=61) showed that a single dose of zoledronic acid administered 6 months after the last denosumab injection maintained lumbar spine BMD at 24 months post-denosumab, while untreated patients lost an average of 5.6% lumbar spine BMD over the same period [9].

This transition is not optional in high-risk patients. It is a clinical requirement.

Safety Profiles Side by Side

Upper GI Events

Alendronate's most common adverse effects are upper gastrointestinal: esophageal irritation, esophagitis, and gastric ulceration. The manufacturer's prescribing information and post-marketing data report esophageal adverse events in roughly 1 to 2% of users per year. Patients must take the tablet with a full 240 mL glass of water, remain upright for at least 30 minutes, and avoid food for at least 30 minutes after dosing.

Denosumab has no GI mechanism of action. Its adverse effects are primarily injection-site reactions (5 to 6% incidence in FREEDOM), hypocalcemia (particularly in vitamin D-deficient patients), and a modest increase in skin and urinary tract infections. Cellulitis occurred in 0.3% of denosumab recipients versus 0.1% in placebo in FREEDOM [2].

Cardiovascular and Cancer Risk

Neither drug has demonstrated a statistically significant increase in cardiovascular events in their respective key trials. A 2015 meta-analysis in the British Medical Journal found no elevated risk of serious cardiovascular events with denosumab compared with placebo or bisphosphonates (relative risk 1.02, 95% CI 0.93 to 1.11) [10]. Cancer risk signals for denosumab emerged in an early analysis of FREEDOM but were not sustained in the long-term extension data or subsequent regulatory reviews.

Cost, Coverage, and Practical Access

Alendronate is among the least expensive osteoporosis drugs available. Generic 70 mg weekly tablets retail for $10, $25 per month at most U.S. Pharmacies, and the drug is on most Tier 1 formulary lists.

Denosumab's cost is an order of magnitude higher. The branded Prolia injection costs $1,200, $1,500 per dose without insurance, translating to $2,400, $3,000 annually. Medicare Part B covers denosumab when administered in a clinical setting, but co-pays apply. Most commercial insurers require prior authorization documenting bisphosphonate intolerance or treatment failure before approving denosumab for osteoporosis.

The Endocrine Society's 2019 clinical practice guideline states: "In postmenopausal women at high risk for fractures, we recommend treatment with alendronate, risedronate, zoledronic acid, or denosumab (strong recommendation, high-quality evidence)" [11]. The guideline does not position denosumab as a second-line agent per se, but the cost and access barriers in practice mean most physicians initiate with an oral bisphosphonate when the patient can tolerate it.

Who Should Start on Each Drug?

Start Alendronate First When:

The patient is newly diagnosed with osteoporosis, has no GI contraindications, has normal renal function (eGFR above 35 mL/min), and cost or insurance access is a concern. Alendronate has 27+ years of post-marketing safety data, a strong generic supply, and fracture reduction evidence that remains clinically relevant.

Start Denosumab First When:

The patient has documented intolerance to oral bisphosphonates, has CKD with eGFR below 35 mL/min, has very high fracture risk requiring the fastest achievable BMD gains, or has a prior fracture on bisphosphonate therapy. Clinicians prescribing denosumab as first-line therapy should document a clear plan for managing discontinuation before the first injection is given.

Per the 2020 American Association of Clinical Endocrinology (AACE) guidelines, "patients at very high risk of fracture (T-score below -3.0, prior hip or vertebral fracture, or FRAX 10-year major osteoporotic fracture probability above 30%) may derive more benefit from anabolic or higher-potency anti-resorptive therapy as initial treatment" [12].

Monitoring on Each Drug

Both agents require the same baseline workup: serum calcium, 25-hydroxyvitamin D, creatinine, and a baseline DXA scan. Monitoring diverges after initiation.

For alendronate, repeat DXA is typically performed at 2 years. If BMD is stable or improving and no fractures have occurred, guidelines support extending the interval to 3 to 5 years. Bone turnover markers (serum CTX or urine NTX) are optional but useful in patients where adherence is uncertain.

For denosumab, DXA is repeated at 1 to 2 years. Serum calcium should be checked within 2 weeks of each injection in patients with vitamin D deficiency or CKD. Given that denosumab must be continued indefinitely or transitioned carefully to a bisphosphonate, the monitoring conversation at initiation should include a long-term treatment plan. Patients who lose follow-up after starting denosumab face measurable rebound fracture risk.